Argenx
ARGX
#562
Rank
S$47.17 B
Marketcap
$776.44
Share price
-1.73%
Change (1 day)
52.71%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): -S$88.73 Million

According to Argenx 's latest financial reports the company's current earnings are S$1.85 Billion. In 2023 the company made an earning of -S$0.41 Billion, an increase over its 2022 earnings that were of -S$0.98 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -S$88.73 Million-78.19%
2023 -S$0.41 Billion-58.25%
2022 -S$0.98 Billion
2019 -S$0.27 Billion124.95%
2018 -S$0.12 Billion132.04%
2017 -S$50.95 Million54.86%
2016 -S$32.91 Million33%
2015 -S$24.74 Million13.63%
2014 -S$21.77 Million46.25%
2013 -S$14.89 Million